Equities

EKF Diagnostics Holdings PLC

EKF Diagnostics Holdings PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)28.12
  • Today's Change-0.88 / -3.03%
  • Shares traded44.44k
  • 1 Year change+8.15%
  • Beta0.3404
Data delayed at least 20 minutes, as of Sep 20 2024 11:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in GBX

The 3 analysts offering 12 month price targets for EKF Diagnostics Holdings PLC have a median target of 37.00, with a high estimate of 39.00 and a low estimate of 29.00. The median estimate represents a 27.59% increase from the last price of 29.00.
High34.5%39.00
Med27.6%37.00
Low0.0%29.00

Earnings history & estimates in GBX

EKF Diagnostics Holdings PLC reported annual 2023 earnings of 1.14 per share on Mar 20, 2024.
Average growth rate+23.88%
More ▼

Revenue history & estimates in GBP

EKF Diagnostics Holdings plc had revenues for the full year 2023 of 52.61m. This was 21.05% below the prior year's results.
Average growth rate+7.77%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.